Abstract
Raltegravir is the first integrase inhibitor approved for treatment of HIV-infected patients harboring multiresistant viruses.
| Originalsprog | Engelsk |
|---|---|
| Tidsskrift | Clinical Epidemiology |
| Vol/bind | 2 |
| Sider (fra-til) | 145-51 |
| Antal sider | 7 |
| ISSN | 1179-1349 |
| Status | Udgivet - 1 jan. 2010 |
Fingeraftryk
Dyk ned i forskningsemnerne om 'Clinical, virological and immunological responses in Danish HIV patients receiving raltegravir as part of a salvage regimen'. Sammen danner de et unikt fingeraftryk.Citationsformater
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS